How hayfever works: The Full Evidence

What percentage of hayfever sufferers also have asthma, and how are the conditions linked?

What the research says

Among individuals with allergic rhinitis, approximately 10-40% also have asthma, while conversely, 40-90% of asthma patients have comorbid allergic rhinitis — a directionality confirmed by a Chinese meta-analysis reporting 10.17% asthma prevalence in AR patients versus 38.97% AR prevalence in asthma patients. US national survey data (NHIS 2021) further indicate that over 80% of adults with asthma report allergy symptoms including rhinitis, underscoring the strong and consistent epidemiological association. Allergic rhinitis is also an independent risk factor for subsequent asthma development, and rhinitis diagnosis frequently precedes asthma onset.

How it works

Both conditions share a common Th2-mediated inflammatory pathway involving IgE sensitization, mast cell degranulation, eosinophilic infiltration, and release of cytokines (IL-4, IL-5, IL-13) across upper and lower airway mucosa — the basis of the 'united airway' or 'one airway, one disease' hypothesis. Additional mechanisms include post-nasal drip triggering vagal bronchoconstrictive reflexes and systemic spread of nasal allergen-induced inflammation to distal bronchial tissue.

---

Does treating allergic rhinitis aggressively reduce the risk of developing asthma?

What the research says

Aggressive treatment of allergic rhinitis (AR) shows differential effects depending on the intervention: allergen immunotherapy (AIT) has the strongest evidence for potentially preventing progression to asthma by modifying underlying atopy, while pharmacotherapies such as intranasal corticosteroids (INCS) and antihistamines primarily improve asthma control in patients with coexisting disease rather than preventing new-onset asthma. AR is an established independent risk factor for asthma development, and early intervention—particularly with AIT—may interrupt this progression, though large long-term RCTs confirming asthma incidence reduction are still lacking. Leukotriene receptor antagonists show the least benefit for asthma outcomes in this context.

How it works

The 'united airway' hypothesis posits that AR and asthma are manifestations of a single chronic inflammatory process, whereby nasal Th2-driven eosinophilic inflammation and cytokine release spread systemically or via aspiration to induce lower airway hyperresponsiveness. AIT uniquely targets this shared pathophysiology by inducing immunological tolerance and modifying the underlying atopic response, whereas INCS and antihistamines only suppress local nasal inflammation without altering the fundamental allergic disease trajectory.

---

What is the atopic march and how does childhood eczema predict later hayfever and asthma?

What the research says

The atopic march describes a sequential progression of allergic diseases beginning with atopic dermatitis (eczema) in infancy, followed by allergic rhinitis (hay fever) and asthma in later childhood or adulthood. Longitudinal birth cohort studies consistently demonstrate that childhood eczema significantly predicts subsequent development of atopic asthma and hay fever, with affected children carrying approximately a 50% risk of developing asthma. However, the march is not strictly linear or universal—co-occurrence, variable sequencing, and non-progression are common, and eczema predicts atopic but not non-atopic asthma specifically.

How it works

Filaggrin gene mutations and skin barrier dysfunction in eczema allow epicutaneous allergen penetration and Staphylococcus aureus colonization, driving Th2-skewed immune responses (IL-4, IL-13, IgE production, eosinophilia) that systemically predispose to nasal mucosal inflammation (allergic rhinitis) and airway hyperreactivity (asthma). Importantly, allergic sensitization appears to be a critical intermediary step, as sensitized children with atopic dermatitis show substantially stronger progression to respiratory atopic disease than non-sensitized children.

---

How does chronic sinusitis overlap with and complicate allergic rhinitis?

What the research says

Allergic rhinitis and chronic rhinosinusitis (CRS) are highly comorbid conditions, with allergy present in approximately 34% of adult CRS patients and up to 53% of pediatric CRS cases, though the relationship is strongest for specific CRS subtypes—central compartment atopic disease (CCAD) and allergic fungal rhinosinusitis (AFRS)—rather than CRS as a whole. Comorbid allergic rhinitis worsens CRS outcomes, contributes to treatment refractoriness, and is associated with higher rates of asthma, increased healthcare utilization, and greater systemic burden including elevated risks of anxiety and depression. Both conditions share type 2 eosinophilic inflammatory pathways and respond to similar biologic therapies, supporting a mechanistic rather than merely coincidental overlap.

How it works

Both AR and CRS involve shared type 2 immune dysregulation characterized by eosinophilic inflammation, IgE-mediated responses (including local mucosal IgE production), and cytokine signaling that perpetuates sinonasal inflammation across contiguous airway tissues, consistent with the unified airway theory. Shared genetic susceptibilities, including overlapping single-nucleotide polymorphisms and comorbidity-associated gene expression profiles (e.g., in CRSwNP), further suggest a common biological substrate rather than independent disease processes.

---

Does allergic conjunctivitis require different treatment than nasal allergy symptoms?

What the research says

Allergic conjunctivitis (AC) frequently coexists with allergic rhinitis (AR) as part of 'allergic rhinoconjunctivitis,' but does require distinct and targeted treatment beyond systemic or intranasal therapies alone. While oral second-generation antihistamines and intranasal corticosteroids used for AR provide some benefit for ocular symptoms, topical ocular therapies—including ophthalmic antihistamines, mast cell stabilizers, and topical corticosteroids—are often necessary to adequately control AC symptoms. Ophthalmic antihistamines are at least as effective as oral antihistamines for ocular symptoms and offer faster local onset, supporting their use as an adjunct or alternative in patients with significant conjunctival involvement.

How it works

Both AR and AC share IgE-mediated mast cell activation and mucosal immune responses, but the conjunctival tissue has distinct local immunological dynamics, including direct allergen exposure and a unique tear film environment, that systemic or intranasal agents may not sufficiently address. A proposed nasal-ocular reflex pathway may also partially link nasal and ocular symptom generation, though local conjunctival treatment targets the tissue-specific inflammatory cascade more directly.